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Abstract 
Background: The Mediterranean diet is a healthy diet with positive scientific evidence of preventing chronic 
diseases. Bioactive components support the healthy properties of the Mediterranean diet. Antioxidants and fiber, 
two components of the Mediterranean diet, are key functional nutrients for healthy eating and nutrition. Wine grape 
pomace is a rich source of these dietary constituents and may be beneficial for human health. Our hypothesis was 
that the intake of red wine grape pomace flour (WGPF) prepared from red wine grapes (Cabernet Sauvignon variety) 
reduced the metabolic syndrome in humans. To evaluate the effect of WGPF on components of metabolic syn-
drome we design a 16-week longitudinal intervention study. Thirty-eight males, 30–65 years of age, with at least one 
component of metabolic syndrome, were randomly assigned to either the intervention group (n = 25) or the control 
group (n = 13). At lunch, the intervention group was given 20 g of WGPF per day, which contained 10 g of dietary 
fiber, 822 mg of polyphenols and an antioxidant capacity of 7258 ORAC units. Both groups were asked to maintain 
their regular eating habits and lifestyles. Clinical evaluation, anthropometric measurements and biochemical blood 
analyses were done at the beginning and the end of the study.
Results: WGPF intake significantly decreased systolic and diastolic blood pressure as well as fasting glucose levels. 
Plasma γ-tocopherol and δ-tocopherol increased and carbonyl group in plasma protein decreased in WGPT group, 
significantly. No significant effect was observed for waist circumference, HDL cholesterol, triglycerides, total antioxi-
dant capacity and vitamin C in and between groups. The group-dependent magnitude of the differences between 
the baseline and final postprandial insulin values and γ-tocopherol concentrations was statistically significant.
Conclusions: The consumption of WGPF-rich in fiber and polyphenol antioxidants, as a food supplement in a regular 
diet improves blood pressure, glycaemia and postprandial insulin. In addition, increased antioxidant defenses and 
decreased oxidative protein damage indicating attenuation of oxidative stress. WGPF might be a useful food ingredi-
ent for health promotion and chronic disease prevention.
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Background
Lifestyle changes, including healthy eating, exercise, and 
giving up smoking, constitute the most powerful tools 
to fight chronic diseases, which are the main causes 
of disability and death in the developed and develop-
ing world [1]. Among various conditions, patients with 
metabolic syndrome are at very high chronic disease risk. 
The increased risk associated with metabolic syndrome 
appears to be linked to higher levels of oxidative stress 
[2]. Recently, much attention has been paid to evidence 
that postprandial oxidative stress contributes to the 
development of cardiovascular disease and diabetes [3–
7]. Thus, managing oxidative stress can be an important 
factor in managing the risk of chronic disease.
Mediterranean diets (MD) are considered as valuable 
preventive measures since several studies have shown 
that their intake is associated with lower incidence and 
prevalence of chronic diseases, mainly cardiovascu-
lar diseases, and longer life expectancy in the countries 
where a MD is consumed or in subgroups exhibiting a 
higher MD score [8, 9]. In 2013, the PREDIMED study, 
a primary prevention trial, reported the benefits of a MD 
in reducing the incidence of major cardiovascular events 
among a high-risk population [10]. A relatively large con-
sumption of olive oil, poultry, fish, fruits, vegetables and 
cereals, a moderate intake of red wine, and a low con-
sumption of red meats characterize MD.
The health effects of different diets can be explained by 
the positive functional properties of key nutrients. The 
bioactive components that apparently support the healthy 
properties of MD are antioxidants, fiber, mono and polyun-
saturated fats, and phytochemicals [11]. Vegetables, fruits 
and legumes, which are rich in antioxidants and fiber, are 
associated with a lower incidence of metabolic syndrome 
and chronic diseases [12, 13]. Wine is also a source of poly-
phenol antioxidants and, when consumed in moderation, is 
associated with reduced risk of cardiovascular diseases [14].
Traditionally, dietary fiber and antioxidants are 
addressed separately as unrelated dietary compounds. 
Saura-Calixto has introduced the concept of antioxidant 
dietary fiber because ≈50 % of total dietary antioxidants, 
mainly polyphenolics, are transported along the small 
intestine linked to dietary fiber [15, 16]. These antioxi-
dants are released from the fiber matrix within the colon 
by the action of bacterial microbiota, generating bioac-
tive metabolites and an antioxidant environment [17]. 
Thus, it is proposed that the transport of dietary antioxi-
dants through the gastrointestinal tract may be an essen-
tial function of dietary fiber [16].
Antioxidant dietary fiber is present in fruits and vegeta-
bles and derived products, such as grapes and apple pom-
ace and mango peel powder [18]. Thus, fruit byproducts 
represent rich sources of dietary fiber and antioxidants 
with beneficial bioactive properties. In this regard, wine 
grape pomace flour (WGPF), made from seed and skin 
residues obtained from grapes during winemaking, con-
tains high levels of phenolic compounds and dietary fiber.
In this study, we prepared flour from WGPF as a func-
tional food ingredient to increase the daily intake of die-
tary fiber and bioactive antioxidant compounds. Based 
on the current evidence, we hypothesized that the daily 
intake of WGPF reduced the metabolic syndrome in 
adult subjects. On this basis, we conducted a longitudi-
nal intervention study including male volunteers with at 
least one component of metabolic syndrome, who were 
randomly assigned to either the intervention group or the 
control group, to test the effects of dietary supplementa-
tion with this WGPF on components of metabolic syn-
drome, plasma antioxidants and protein damage.
Results
Subjects that withdrew from the study and side effect 
of WGPF
Thirty-eight participants completed the protocol: 13 con-
trols and 25 subjects in the intervention group. After 
the initial randomization, three participants in the con-
trol group quit the study: one underwent a programmed 
cholecystectomy; another needed medical treatment that 
involved anti-inflammatory drugs to treat pain, and a third 
did not want to repeat blood tests. In the intervention 
group, six participants dropped out of the study: one had 
to undergo kidney surgery, two disliked blood sampling, 
and three declined to consume WGPF. Although the with-
drawal, no statistical differences in baseline measurements 
were found between groups (Table 1). Also, some partici-
pants reported side effects during the period when they 
consumed WGPF: 7, exhibited increased intestinal gas; 2, 
heartburn; 2, slight episodes of constipation, 7, regulariza-
tion of intestinal transit; 6, softer stools; 3, increased appe-
tite; 2, dyspepsia; 2, gastroesophageal reflux.
Dietary evaluation and anthropometric measurements
The Mediterranean diet score did not change significantly 
in any group by the end of the study. Table  2 shows the 
anthropometric parameters of the WGPF and control 
groups at baseline and after the intervention period. During 
the study, a statistically significant increase in body mass 
index (BMI) was observed in the control group (P < 0.05). 
No other statistically significant changes were found in 
this group. There were no variations in anthropometric 
variables in the WGPF supplemented group, including no 
change in BMI during the intervention period.
Effects of WGPF on metabolic syndrome components
Table  3 shows data on components of metabolic syn-
drome in the WGPF and control groups at baseline and 
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after the intervention period. After 16  weeks of supple-
mentation with 20  g/day WGPF, systolic and diastolic 
blood pressure and fasting glucose levels decreased sig-
nificantly (P  <  0.05). Waist circumference, HDL choles-
terol and triglycerides were not affected. No changes 
were observed in these components in the control group.
In the control group, initially 23 % (3/13) had abdomi-
nal obesity, 54  % (7/13) high triglycerides, 31  % (4/13) 
low HDL cholesterol, 38  % (5/13) high blood pressure, 
8 % (1/13) high glucose and 23 % (3/13) were diagnosed 
with metabolic syndrome at baseline. After the 16-week 
intervention, 31  % (4/13) of control subjects showed 
abdominal obesity, 38  % (5/13) high triglycerides, 54  % 
(7/13) low HDL cholesterol, 31 % (4/13) high blood pres-
sure, and 0 % high glucose. During the study, no signifi-
cant changes were observed in percentages of subjects 
presenting metabolic syndrome criteria in the control 
group, 23 % (3/13).
In the WGPF supplemented group, 52  % (13/25) pre-
sented abdominal obesity, 36 % (9/25) high triglycerides, 
24 % (6/25) low HDL cholesterol, 52 % (13/25) high blood 
pressure, 20 % (5/25) high glucose, and 32 % (8/25) were 
diagnosed with metabolic syndrome at baseline. After the 
16-week intervention, 52 % (13/25) exhibited abdominal 
obesity, 40 % (10/25) high triglycerides, 28 % (7/25) low 
HDL cholesterol, 20  % (5/25) high blood pressure, 8  % 
(2/25) high glucose and 24 % (6/25) had metabolic syn-
drome. After intake of WGPF, the percentage of subjects 
with high blood pressure according to the metabolic syn-
drome definition had decreased significantly (P = 0.035).
Overall, WGPF significantly reduced the average num-
ber of metabolic syndrome components present per 
subject from 1.84 ± 1.62/participant to 1.48 ± 1.29/par-
ticipant (P < 0.05). No change was observed in the con-
trol group.
With regard to the diagnosis of metabolic syndrome 
in the control group, the prevalence of this risk condi-
tion remained unchanged (23  %) during this study. In 
contrast, a non-significant trend to a lower prevalence of 
metabolic syndrome was detected from baseline (32  %) 
to after WGPF supplementation (24 %).
Effects of WGPF on additional metabolic factors
Total cholesterol and LDL cholesterol did not change sig-
nificantly within and between groups by the end of the 
study. Table 4 shows findings from an oral glucose toler-
ance test (OGTT) with glucose, insulin measurements, 
insulin resistance (evaluated by HOMA) and glycosylated 
hemoglobin in the WGPF and control groups at baseline 
and after the intervention. As mentioned above, a statis-
tically significant decrease was observed in fasting glu-
cose in the WGPF supplemented group, but not in the 
Table 1 Baseline clinical, anthropometric, and  biochemi-
cal characteristics of experimental and control groups
Values are mean ± SD. Data are tested by Students t-test. No statistical 
differences in baseline measurements were found between groups
LDL low-density lipoprotein, HDL high-density lipoprotein, GOT glutamic 
oxalacetic transaminase, GPT glutamic pyruvic transaminase, ALP alkaline 
phosphatase
Experimental Control
Number of volunteers 25 13
Age (years) 44.5 ± 9.3 43.1 ± 8.4
Body mass index (kg/m2) 29.1 ± 3.9 27.9 ± 3.5
Body fat (%) 29.1 ± 5.3 26.8 ± 4.0
Waist circumference (cm) 102.7 ± 9.9 98.1 ± 7.0
Total cholesterol (mg/dL) 185.7 ± 33.9 197.8 ± 42.3
LDL cholesterol (mg/dL) 109.8 ± 28.5 120.6 ± 32.5
HDL cholesterol (mg/dL) 46.4 ± 10.7 41.2 ± 8.6
Triglycerides (mg/dL) 147.5 ± 88.2 179.8 ± 96.5
Systolic blood pressure (mmHg) 127.1 ± 11.5 122.4 ± 12.4
Diastolic blood pressure (mmHg) 79.7 ± 8.3 80.2 ± 6.6
Hemoglobin (g/dL) 15.4 ± 0.7 15.5 ± 1.0
Glucose (mg/dL) 92.7 ± 5.8 88.9 ± 5.8
Insulin (mg/dL) 12.5 ± 8.3 10.3 ± 4,6
GOT (U/L) 22.6 ± 5.8 26.2 ± 9.9
GPT (U/L) 27.5 ± 14.2 31.5 ± 12.6
ALP (U/L) 81.6 ± 16.1 84.4 ± 24.2
Bilirubin (mg/dL) 0.64 ± 0.30 0.65 ± 0.24
Table 2 Anthropometric characteristics in groups at baseline and 16 weeks
Values are mean ± SD. Data are tested by Students t-test. Means within a group with different superscript letters are significantly different; P < 0.05 paired t-test
Experimental Control
Basal (0 weeks) Final (16 weeks) Basal (0 weeks) Final (16 weeks)
Weight (kg) 86.7 ± 13.6 87.3 ± 13.4 81.1 ± 11.7 82.3 ± 11.5
Body mass index (kg/m2) 29.1 ± 3.9 29.3 ± 3.8 27.9 ± 3.5a 28.3 ± 3.6b
Body fat (%) 29.1 ± 5.3 28.7 ± 5.3 26.8 ± 4.0 26.3 ± 4.6
Basal metabolism (kcal) 1735 ± 399 1824 ± 179 1751 ± 171 1768 ± 163
Skeletal muscle (%) 33.0 ± 2.9 33.2 ± 2.9 34.5 ± 2.2 34.8 ± 2.5
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control group (Table 3). After the 16-week intervention, 
there were no statistically significant changes in fasting 
insulin, HOMA, postprandial glucose, insulin and glyco-
sylated hemoglobin between the two groups. While post-
prandial insulin levels increased from the baseline to the 
end of the study among control subjects, levels decreased 
among the members of the WGPF group over the same 
period. The group-dependent magnitude of the differ-
ences between the initial and final postprandial insulin 
values was statistically significant (P < 0.05).
Effects of WGPF on antioxidant vitamins, antioxidant 
capacity and oxidative damage in proteins
Table  5 shows data on plasma tocopherols, vitamin C, 
antioxidant capacity and carbonyl groups in proteins, 
in the WGPF and control groups at baseline and after 
the intervention period. Alpha-tocopherol and anti-
oxidant capacity measure as TRAP did not change sig-
nificantly within and between groups by the end of the 
study. Vitamin C increased and antioxidant capacity, 
measure as DPPH, decreased from the baseline to the 
end of the study within control and WGPF groups sig-
nificantly. After the 16-week intervention γ-tocopherol 
and α-tocopherol increased significantly in WGPF 
group. Additionally, while δ-tocopherol concentrations 
increased from the baseline to the end of the study 
among the members of the WGPF group, concentra-
tions decreased among control subjects over the same 
period. The group-dependent magnitude of the differ-
ences between the initial and final γ-tocopherol values 
was statistically significant (P  <  0.05). Protein dam-
age measured as carbonyl groups in plasma proteins 
decreased significantly in WGPF group by the end of 
the study.
Discussion
Wine grape pomace flour prepared from red wine grape, 
Cabernet Sauvignon variety, is especially rich in antioxi-
dants and fiber, two bioactive components of human diet 
with healthy properties. Our hypothesis was that WGPF 
consumption decreases the risk of developing metabolic 
syndrome, supporting its potential benefit for preventing 
cardiovascular disease and diabetes. We chose a group of 
men with at least one diagnostic criterion of metabolic 
syndrome in order to enhance the chance of detecting 
significant effects.
Table 3 Metabolic syndrome components in groups at baseline and 16 weeks
Values are mean ± SD. Student t-test for paired samples was used to analyze differences of means within groups. Student t-test for independent samples was used to 
analyze differences of means between groups. Wilcoxon signed rank-sum test was used to compare the number of positive criteria for metabolic syndrome. Means 
within a group with different superscript letters are significantly different; P < 0.05 paired t test
Experimental Control
Basal (0 weeks) Final (16 weeks) Basal (0 weeks) Final (16 weeks)
Waist circumference (cm) 102.7 ± 9.9 102.5 ± 10.5 98.1 ± 7.0 98.8 ± 7.4
Systolic blood pressure (mmHg) 127.1 ± 11.5a 122.8 ± 8.5b 122.4 ± 12.4 120.0 ± 13.3
Diastolic blood pressure (mmHg) 79.7 ± 8.3a 74.4 ± 5.6b 80.2 ± 6.6 76.4 ± 9.3
Fasting glucose (mg/dL) 92.7 ± 5.8a 89.4 ± 7.9b 88.9 ± 5.8 86.9 ± 5.4
HDL cholesterol (mg/dL) 46.4 ± 10.7 46.5 ± 10.8 41.2 ± 8.6 42.7 ± 14.4
Triglycerides (mg/dL) 147.5 ± 88.2 153.0 ± 98.6 179.8 ± 96.5 157.4 ± 81.6
Number of positive criteria for metabolic syndrome 1.84 ± 1.62a 1.48 ± 1.29b 1.54 ± 1.13 1.54 ± 1.13
Metabolic syndrome prevalence (%) 32 24 23 23
Table 4 Oral glucose tolerance test, HOMA and glycosylated hemoglobin in groups at baseline and 16 weeks
Values are mean ± SD. Student t-test for paired samples was used to analyze differences of means within groups. Student t-test for independent samples was used to 
analyze differences of means between groups. Means within a group with different superscript letters are significantly different; P < 0.05 paired t test
* Indicate statistically significant differences in the changes produced by the intervention between the groups (P < 0.05, paired t test)
Experimental Control
Basal (0 weeks) Final (16 weeks) Basal (0 weeks) Final (16 weeks)
Postprandial glycemia 120 min (mg/dL) 85.0 ± 28.9 89.1 ± 34.2 82.7 ± 19.1 83.7 ± 34.8
Fasting insulin (mg/dL) 12.5 ± 8.3 11.8 ± 8.9 10.3 ± 4.6 8.9 ± 4.4
Postprandial insulin 120 min (mg/dL) 67.1 ± 68.3 60.3 ± 59.6* 57.8 ± 57.0 77.0 ± 97.2*
HOMA 2.90 ± 2.05 2.65 ± 2.17 2.30 ± 1.10 1.93 ± 1.02
Glycosylated hemoglobin (%) 5.2 ± 0.3a 5.5 ± 0.3b 5.1 ± 0.3a 5.3 ± 0.3b
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WGPF contains an antioxidant/fiber complex, in which 
polyphenols are transported along the gastrointestinal 
tract linked to fiber components. WGPF includes solu-
ble or extractable polyphenols with low or intermedi-
ate molecular mass, which appear to be absorbed from 
the digestive tract with systemic effects [15]. Neverthe-
less, many WGPF polyphenols are non-absorbable/non-
extractable high molecular mass proanthocyanidins [16]. 
After reaching the large intestine, these antioxidants are 
processed by colonic microbiota producing metabolites 
with physiological properties [19].
Antioxidant dietary fiber and extractable and non-
extractable polyphenol content in pomace obtained 
during winemaking usually ranges from 50 to 75 %, 1 to 
9 % and 15 to 30 % by dry matter, respectively [15]. Our 
WGPF contains 52 % dietary fiber (7 % soluble and 93 % 
insoluble), and 4.4 % of extractable polyphenols with an 
antioxidant capacity of 362.9 ORAC (µmol  TE/g  dry 
matter). A similar product obtained from Cencibel wine 
grape in Spain showed an antioxidant capacity of 214.2 
ORAC units [20]. Thus, flour derived from Cabernet Sau-
vignon WGPF exhibits a composition profile that sug-
gests potential health benefits.
Indeed, dietary fiber (or non-starch polysaccharides) is 
a collective term for a variety of plant substances resist-
ant to digestion by human gastrointestinal enzymes. 
Structural fiber (cellulose, lignin, and hemicelluloses) is 
insoluble, whereas gel-forming fiber (pectins, gums, and 
mucilages) is water-soluble [21]. Intervention trials have 
shown that soluble dietary fiber lowers blood cholesterol 
concentrations, reduces blood pressure, promotes body 
weight loss, and improves insulin sensitivity, eventually 
leading to reduced risk of cardiovascular disease [21, 22].
Based on proximal analysis of WGPF (Table  6), sup-
plementation with 20 g of WGPF increased the intake of 
dietary fiber by 9.5 g per day. Previous data from a simi-
lar group of workers disclosed a consumption of 19.5 g/
day of dietary fiber [23]. Thus, we estimated that intake of 
fiber might have reached ≈30 g/day in the WGPF supple-
mented group during the study. In addition, this amount 
of WGPF provided 7,258 ORAC units/day of antioxidant 
capacity, which is equivalent to consuming two glasses of 
red wine per day.
We observed a statistically significant lowering of 
blood pressure after WGPF intake. Previous studies have 
shown that soluble dietary fiber reduces blood pressure 
[21, 22]. Furthermore, fiber, especially soluble types, 
also improves intestinal potassium and magnesium 
Table 5 Antioxidant vitamins, antioxidant capacity and protein carbonylation in groups at baseline and 16 weeks
Values are mean ± SD. Student t-test for paired samples was used to analyze differences of means within groups. Student t-test for independent samples was used to 
analyze differences of means between groups. Means within a group with different superscript letters are significantly different; P < 0.05 paired t test
* Indicate statistically significant differences in the changes produced by the intervention between the groups (P < 0.05, paired t test)
Experimental Control
Basal (0 weeks) Final (16 weeks) Basal (0 weeks) Final (16 weeks)
α-Tocopherol (µM) 31.67 ± 8.58 32.48 ± 8.73 33.00 ± 10.12 31.75 ± 9.85
γ-Tocopherol (µM) 1.80 ± 0.74a 2.40 ± 1.36b* 1.97 ± 1.07 1.87 ± 0.72*
δ-Tocopherol (µM) 0.70 ± 0.13a 0.79 ± 0.23b 0.74 ± 0.26 0.76 ± 0.24
Vitamin C (µM) 28.66 ± 8.41a 34.58 ± 11.76b 23.16 ± 8.47a 30.21 ± 10.12b
TRAP (µM Trolox Eq.) 491.99 ± 114.69 469.82 ± 105.74 465.92 ± 82.97 424.96 ± 71.65
DPPH (µM Trolox Eq.) 93.47 ± 28.11a 72.05 ± 26.97b 91.04 ± 24.82a 67.16 ± 22.49b
Carbonyl groups (nmol/mg protein) 0.56 ± 0.18a 0.44 ± 0.19b 0.55 ± 0.14 0.54 ± 0.29
Table 6 Composition of wine grape pomace flour
Values are mean ± SD
GE gallic equivalent, C3G cyanidin 3-glucoside, TE Trolox equivalent, n.d. non-
detected
a Nitrogen-free extract minus dietary fiber
g/100 g WGPF




 Dietary fiber 47.70
  Soluble 3.54
  Insoluble 44.20
 Ash 8.41
 Moisture 7.47
Antioxidants and antioxidant capacity
 Polyphenols (mg GE/g) 41.11 ± 3.01
 Anthocyanin (mg C3G/g) 1.49 ± 0.18
 Vitamin C (µg/g) n.d.
 α-tocopherol (µg/g) 53.51 ± 3.69
 γ-tocopherol (µg/g) 12.57 ± 0.71
 δ-tocopherol (µg/g) 0.68 ± 0.07
 ORAC (µmoles TE/g) 362.9 ± 24.4
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absorption, which may have an indirect favorable effect 
on blood pressure [22]. However, the WGPF used in this 
study contains only 7 % of soluble fiber. Consequently, it 
is difficult to attribute the hypotensive effect exclusively 
to this component. Nevertheless, extracts of polyphe-
nols from grape seeds, grape pomace, and/or wine have 
shown positive effects on blood pressure. Polyphenols 
activate endothelial nitric oxide synthase (eNOS) and this 
effect has been suggested as the mechanism that lowers 
blood pressure [24]. The bioavailability of single and 2- or 
3-polymer unit polyphenols also support this mechanism 
[25].
A relatively small fraction (1–9 %) of these polyphenols 
associated with dietary fiber are extractable from WGPF 
[15], so only a minor amount of this form of antioxidants 
are absorbed by the intestine. However, plasma antioxi-
dant capacity increases postprandially, becoming signifi-
cant 8 h after consuming grape pomace [26]. This delayed 
increase is explained by the presence of more complex 
polyphenols (high polymerization proantocyanidins) 
linked to fiber in grape pomace. These proantocyani-
dins reach the colon, where they are partially fermented 
by bacterial microflora along with indigestible carbo-
hydrates. Indeed, colonic fermentation of grape pom-
ace generates metabolites that are detectable in human 
plasma [17]. Fiber-associated antioxidant products 
released by fermentation may explain the reduction in 
blood pressure after WGPF supplementation. Additional 
studies are required to test this hypothesis.
Moreover, we observed a significant reduction in the 
plasma concentrations of fasting glucose in the WGPF 
supplemented group. There is evidence that dietary fiber 
consumption is associated with lower fasting glucose 
levels in diabetic individuals [27]. The mechanisms asso-
ciated with this beneficial effect have not yet been eluci-
dated [28].
We also found, a statistically significant difference, 
when comparing the change in postprandial insulin con-
centrations along the study, among control and WGPF 
groups. There have been few intervention studies on the 
effects of dietary fiber on postprandial glucose and insu-
lin. Recently, an intervention trial reported that a whole-
grain cereal-based diet significantly lowers postprandial 
plasma insulin concentration in individuals with meta-
bolic syndrome [29]. It is likely that bioactive compounds 
in this fiber-enriched ingredient, such as trace miner-
als, phenolic antioxidants, vitamin E or phytoestrogens, 
operating by different unknown pathways may contribute 
to this positive postprandial metabolic effect [30].
In prospective observational studies, normal post-
prandial increases in blood glucose and triglyceride 
levels have been linked to the risk of cardiovascular 
disease and diabetes [3–7]. The evidence suggests that 
postprandial hyperglycemia and hypertriglyceridemia 
cause oxidative stress. Postprandial oxidative stress 
occurs within minutes to hours following consump-
tion of a meal rich in fat, carbohydrates and protein [31, 
32]. Over the long-term, oxidative stress leads to insu-
lin resistance, pancreatic β-cell dysfunction, abnormal 
serum lipids, coagulopathy, systemic inflammation, and 
endothelial dysfunction [33]. Exaggerated postprandial 
spikes in glucose and lipids can also trigger inflamma-
tion, endothelial dysfunction, and sympathetic hyper-
activity [33]. With multiple repetition on a daily basis, 
these postprandial changes that lead to atherosclerosis 
and diabetes. Dietary strategies aimed at attenuating 
these pathogenic alterations provide new opportunities 
to reduce the risk of chronic disease. In fact, consump-
tion of red wine polyphenols and grape seed extract with 
a meal rich in fat, carbohydrates and protein signifi-
cantly reduces postprandial oxidative stress [34–36]. We 
hypothesize that dietary fiber rich in antioxidant in our 
WGPF reduces postprandial oxidative stress and plasma 
oxidative damage when consumed with meals. In accord, 
we observed a significant decrease in protein oxida-
tion in WGPF supplemented group. Oxidative damage 
reduction may partially explain its beneficial effect on 
blood pressure and glucose homeostasis, with important 
implications for the prevention and management of met-
abolic syndrome [24]. Further investigation is needed to 
validate this proposal.
In contrast to earlier studies with pomace with animal 
models and humans [16, 20, 37, 38], our WGPF did not 
influence serum cholesterol levels. In a human trial, sup-
plementation with grape pomace flour obtained from 
Cencibel wine grapes significantly decreased total cho-
lesterol in normo- and hypercholesterolemic subjects 
[20]. Furthermore, LDL cholesterol and triglycerides 
diminished significantly only in hypercholesterolemic 
subjects, who represented 38 % of study participants and 
were mostly women (65 %) [20]. Although the fiber and 
antioxidant composition and dose were similar to those 
in our WGPF, we did not observe any effect on lipid pro-
file. However, our study design included only male sub-
jects with 40  % hypercholesterolemic (total cholesterol 
>200 mg/dL) at baseline. Alternatively, the lack of effect 
in our study may be attributed to differential functional 
properties of wine grape types (e.g., Cabernet Sauvi-
gnon versus Cencibel). In hamsters, different effects were 
observed of a diverse variety of grape pomace in plasma 
total cholesterol and LDL-cholesterol concentrations 
[39].
In terms of antioxidant capacity, measured as DPPH, 
and vitamin C, we observed similar changes in both 
group. They consumed same food at the cafeteria of work 
place, so these variations could be explained by the diet.
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Interestingly we found a significant increase in plasma 
concentrations of γ-tocopherol and δ-tocopherol in 
the WGPF supplemented group. Also, a statistically 
significant difference, when comparing the change in 
γ-tocopherol concentrations along the study, among con-
trol and WGPF groups was detected. The raise in plasma 
concentrations of γ- and δ-tocopherols in the WGPF sup-
plemented group could be explained by the antioxidant 
effect of WGPF polyphenols in the gastrointestinal tract 
[40]. This effect would depend on the quantity of toco-
pherols in the entire diet. Volunteers consumed soybean 
oil that is a good source of γ-tocopherol (80  mg/100  g) 
and δ-tocopherol (27 mg/100 g) [41]. WGPF by its anti-
oxidant capacity would protect these vitamins from its 
oxidation, improving its bioavailability and increasing the 
antioxidant defenses of the volunteers in terms of plasma 
concentration of vitamin E.
The significance of plasma increase of these forms of 
vitamin E on health is matter of discussion [41]. Most 
research of vitamin E has focused on α-tocopherol, 
because it is the predominant form of vitamin E in tis-
sues. Despite well-documented antioxidant and other 
beneficial effects, supplementation with α-tocopherol has 
failed to offer consistent benefits to prevention of chronic 
diseases, as cancer and cardiovascular diseases, in clini-
cal intervention studies in people with adequate nutrient 
status. Current studies show that other forms of vitamin 
E, such as γ-tocopherol and δ-tocopherol have unique 
antioxidant and anti-inflammatory properties in preven-
tion and therapy against chronic diseases. These vita-
min E forms scavenge reactive nitrogen species, inhibit 
cyclooxygenase- and 5-lipoxy-catalyzed eicosanoids, and 
suppress proinflammatory signaling. It has been sug-
gested that γ-tocopherol and δ-tocopherol may be useful 
against inflammation-associated diseases [41].
Strength of the current study was that workers had a 
similar diet during weekdays, because they were offered 
same lunch menus at the cafeteria of the company. Also 
we supervised daily the intake of WGPF during lunch as 
well as similar consumption of regular bread in control 
subjects. However, one limitation of the study was that 
the number of participants who completed the protocol 
in each group was relatively small, because six and three 
participants quit the study in WGPF and control groups, 
respectively. Second, this study was an open-labelled trial 
that may have led to potential biases in the subjects as 
well as in the researchers. Third, we did not measured dif-
ferences in caloric intake at the end of the interventions, 
but no changes in abdominal obesity or body weight were 
detected during the study in both groups suggesting that 
no major differences in energy balance occurred during 
the study. In addition, both groups were encouraged to 
maintain their regular eating habits and lifestyle.
Conclusions
The consumption of WGPF as a food supplement to a 
regular diet, improves some components of metabolic 
syndrome, as blood pressure and glycaemia. Also, post-
prandial insulin levels, measured in an OGTT, were 
reduced. Moreover, fiber and polyphenols-containing 
WGPF increased antioxidant defenses, rising γ- and 
δ-tocopherols and diminishing oxidative protein dam-
age, contributing to a better handling of oxidative stress. 
WGPF seems to be a promising functional ingredient 
that can be incorporated into different food matrices to 
increase fiber and antioxidant consumption and even-




A group of 47 male workers 30–65 years old, who regu-
larly consumed an omnivorous diet, participated in the 
study. All of them gave informed consent and underwent 
a comprehensive medical history, physical examination, 
and clinical chemistry analysis before enrollment. One of 
the inclusion criteria was having at least one of the five 
components of metabolic syndrome.
The presence of metabolic syndrome components was 
defined using the criteria proposed by the Adult Treat-
ment Panel III of the US National Cholesterol Education 
Program: (1) abdominal obesity as waist circumference 
>102 cm for men; (2) low levels (<40 mg/dL for men) of 
serum high density lipoprotein cholesterol; (3) hypertri-
glyceridemia as 150  mg/dL or more; (4) elevated blood 
pressure as 130/85  mmHg or higher; and (5) impaired 
glucose homeostasis as fasting plasma glucose levels of 
100 mg/dL or higher [42].
Volunteers were excluded that were under treatment 
for diabetes mellitus, hypertension or dyslipidemia or 
under pharmacological treatment with drugs that modify 
plasma antioxidant capacity and inflammation. The study 
was approved by the Ethics Committee of the School of 
Medicine at the Pontificia Universidad Católica de Chile 
and was performed in accordance with the ethical stand-
ards laid down in the 1964 Declaration of Helsinki and 
Michael Okpara University, Umudike, Nigeria.
Wine grape pomace flour
Pomace, a byproduct from wine production, was 
obtained from red wine grapes (Cabernet Sauvignon, 
vintage 2011, Maipo Valley, Chile) and stored at −20 °C 
until used. Frozen WGPF was thawed at room tempera-
ture and dried in a forced air dryer at 60  °C until mois-
ture reached less than 12 %. Dried pomace was powdered 
into flour using a hammer mill. WGPF was packaged in 
20-kilo double plastic bags.
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The overall composition of WGPF is shown in Table 6. 
It has a high dietary fiber content (52  % by dry weight) 
determined by the enzymatic–gravimetric method 
AOAC 991.43. In addition, WGPF was sequentially 
extracted three times with acetone/water/acetic acid 
at room temperature for 60  min and supernatants were 
combined and used to measure total polyphenol con-
tent, antioxidant capacity and tocopherols. Polyphe-
nolic compounds (41.11  mg gallic acid equivalent/g) 
were determined by the Folin–Ciocalteu procedure 
[43]. Total anthocyanin content (1.49  ±  0.18  mg/g 
cyanidin 3-glucoide equivalents) was determined by 
AOAC Official Method 2005.02. Antioxidant capac-
ity (362.9 µmoles/g Trolox equivalent) was measured by 
the oxygen radical absorbance capacity (ORAC) assay 
[44]. There was not detected vitamin C (l-ascorbic 
acid) analyzed using the HPLC method described by 
Kimoto et  al. [45]. Tocopherol contents (α-tocopherol 
53.51 ±  3.69  µg/g; γ-tocopherol 12.57 ±  0.71  µg/g and 
δ-tocopherol 0.68  ±  0.07  µg/g) were determined using 
high-performance liquid chromatography (HPLC) with 
electrochemical detection according to Motchnik et  al. 
[46].
Quantification and identification of polyphenols and 
anthocyanins in WGPF extracts were performed by 
HPLC. The HPLC chromatogram of polyphenol neu-
tral fraction with detection at 360  nm, the HPLC chro-
matogram of polyphenol acid fraction with detection 
at 280  nm and the HPLC chromatogram of polyphenol 
aqueous fraction (anthocyanin fraction) with detection 
at 518  nm. Individual compounds were identified by 
diode array detector (DAD) and standard compounds. 
Phenolic acids (gallic acid; caffeic acid; vanillic acid; pro-
tocatechuic acid; coumaric acid and ferulic acid) con-
centration was 0,065  mg/g WGPF, in which gallic acid 
represented 83  %. Flavonoids (flavanols; flavonols and 
flavanones) concentration was 0.160  mg/g WGPF, in 
which catechin and catechin derivatives represented 
57.8 % and flavonols 22.9 %. Anthocyanin concentration 
was 0.366 mg/g WGPF (mono-glucosides were expressed 
as cyanidin-3-glucoside and di-glucosides as cyanidin-
3,5-diglucoside), in which malvidin and malvidin deriva-
tives represented 65 %.
Study design
The study was a prospective, randomized, controlled 
parallel-group trial. The intervention was carried out at 
a heavy mining machinery company in Santiago, Chile. 
All employees were informed about the study and invited 
to participate. Initially, 47 male workers free of exclusion 
criteria agreed to participate. The number of partici-
pants in each group was chosen based on the variation 
coefficients in the evolution of total cholesterol in the 
intervention and in the control group, observed in a pre-
vious work [47].
For allocation of the participants, a computer-gener-
ated random list was used, prepared by an investigator 
with no clinical involvement in the trial. Participants 
were randomly assigned to either the control (n  =  16) 
or intervention group (n = 31). Both groups were asked 
to maintain their regular eating habits and lifestyles for 
16 weeks, except for the daily intake of 20 g of WGPF by 
the intervention group. WGPF was consumed in bread, 
biscuits or as flour mixed with water during lunch. Bread 
and biscuits with 20  % WGPF were prepared especially 
in a bakery. WGPF intake was supervised every day at 
lunch. Participants were asked to consume the flour sup-
plement with their regular meals on weekends.
Complete follow-up was obtained with a group of 
38 workers, 13 controls and 25 subjects that consumed 
WGPF. Compliance with WGPF consumption was care-
fully monitored. Participants had clinical, nutritional, 
anthropometric and laboratory evaluations at the begin-
ning and end of the study. There were no significant basal 
differences between the two groups in anthropometric, 
blood pressure and biochemical parameters (Table 1).
Mediterranean diet score
Overall food intake was evaluated using a self-reported 
questionnaire with fourteen items that measure adher-
ence to the Mediterranean diet in Chile [23]. This scale 
was designed on the basis of traditional food consump-
tion habits in the European Mediterranean region, with 
selective modifications to incorporate Chilean dietary 
habits. This Mediterranean diet score ranges from 0 
(minimal adherence) to 14 (maximal adherence). There 
were no significant basal differences between the two 
groups in the Mediterranean diet score, with a score of 
5.0 ± 1.32 in the control group and 5.4 ± 1.56 in the sup-
plemented group.
Anthropometric and blood pressure measurements
Height, weight, and percentage of body fat (determined 
by bioimpedance, Omron device model HBF-500INT) 
were recorded at baseline and at the end of the interven-
tion period.
Blood systolic and diastolic pressures were measured 
on the left arm at the heart level after at least 5 min of 
resting in a sitting position and using a mercury sphyg-
momanometer (RIESTER Diplomat®-Presameter). Two 
readings, separated by at least 1 min, were taken and the 
mean value was calculated and recorded. If there was 
more than a 5  mmHg difference between the first and 
second readings, additional readings were obtained and 
then the mean value of the multiple readings was used 
[48].
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Biochemical procedures
Venous blood samples were taken after a 12-h fasting 
period and collected in heparin, citrate and anticoagu-
lant-free BD Vacutainer® tubes. Glucose, total choles-
terol, HDL cholesterol, LDL cholesterol and triglycerides 
were measured in serum using a spectrophotometer 
autoanalyzer (Hitachi 917; Roche Diagnostics®) with rea-
gent kits purchased from the manufacturer.
An OGTT was performed after overnight fasting. Sub-
jects ingested a solution containing 75 g of dextrose, and 
venous blood samples were obtained at 0 and 120 min to 
determine plasma glucose and insulin levels. Insulin was 
measured by electrochemiluminescence immunoassay 
(ECLIA; Roche Diagnostics®).
For determination of l-ascorbic acid, blood samples 
kept in ice were analyzed the same day that blood was 
drawn. l-Ascorbic acid was determined by spectropho-
tometry [46].
Tocopherols (α-tocopherol, γ-tocopherol and 
δ-tocopherol) were determined in plasma using HPLC 
with electrochemical detection according to Motchnik 
et al. [46].
The total plasma antioxidant capacity was evalu-
ated by total radical trapping potential (TRAP) and 
2,2-diphenyl-1-picrylhydrazyl (DPPH) assays. Trolox® 
(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic 
acid) (Trolox),was chosen as a standard antioxidant. The 
procedure for TRAP employs luminol-enhanced chemi-
luminescence measurements, method developed by 
Wayner et al. [49]. DPPH assay was assessed by the spec-
trophotometric method adapted from Pisoschi et al. [50].
Determination of carbonyl groups in oxidized plasma 
proteins was assessed by derivatization with dinitro-
phenylhydrazine (DNPH). Spectrophotometric meas-
urement of plasma reactive carbonyl derivatives was 
performed and calculated using the extinction coef-
ficient of DNPH-reactive carbonyl derivatives at 
370  nm  =  22  ×  103  L  mol−1  cm−1 and expresses as 
μmol/g proteins Levine et al. [51].
Statistical analysis
Continuous variables are shown as mean and standard 
deviation, while categorical variables as the number of 
cases and percentage. The student t-test for independ-
ent samples and the Chi square test were used to analyze 
differences of means and proportions between the two 
groups, respectively. The student t-test for paired samples 
and McNemar’s test were used to analyze differences of 
means and proportions within each group. When appro-
priate, the Wilcoxon signed rank-sum test was used to 
compare paired medians. All P values were two-tailed 
and a value <0.05 was considered to be statistically signif-
icant. Data processing and statistical analyses were done 
with the SAS statistical software package version 9.1 for 
Windows.
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